Royalty Report: Drugs, Pharmaceuticals, Disease – Collection: 64742


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 6


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Disease
  • Therapeutic
  • Cancer
  • Gastrointestinal
  • Respiratory
  • Biotechnology
  • Vaccine

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 64742

License Grant
The company entered into an agreement to assume the remaining commercial rights to Omeclamox-Pak for the United States.  The Company will continue to market and sell Omeclamox-Pak and is now responsible for the supply chain, national accounts and all sales promotion as part of the agreement.  The Company will continue promotion to the gastroenterology community through its field sales force and seek a new co-promotion partner with national primary care capabilities in the U.S.
License Property
Omeclamox-Pak is a branded prescription product that combines omeprazole, amoxicillin and clarithromycin for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease.
Field of Use
Helicobacter pylori (H. pylori) is a type of bacteria. These germs can enter your body and live in your digestive tract. After many years, they can cause sores, called ulcers, in the lining of your stomach or the upper part of your small intestine.
A duodenal ulcer is a peptic ulcer that develops in the first part of the small intestine (duodenum).

IPSCIO Record ID: 314125

License Grant
Pursuant to the agreement, the companies will co-develop a novel next-generation therapy for the eradication of H. pylori infection.  The Licensee will receive the exclusive European rights to the new drug. Licensee will become the exclusive worldwide manufacturer for the novel next-generation therapy for the eradication of H. pylori infection, Movantik® (naloxegol) and RHB-204 for pulmonary nontuberculous mycobacteria (NTM) infections.
License Property
H. pylori infection is a type of bacteria. These germs enter your body and live in your digestive tract which may cause sores, called ulcers or stomach cancer.

Movantik® is a prescription medicine used to treat constipation that is caused by prescription pain medicines called opioids.

Movantik® is a proprietary once-daily oral PAMORA approved by the U.S. Food and Drug Administration for the treatment of OIC in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g. weekly) opioid dosage escalation

RHB-204 is used for pulmonary nontuberculous mycobacteria (NTM) infections. Pulmonary nontuberculous mycobacteria (NTM) disease is a chronic and debilitating lung disease caused by ubiquitous environmental bacteria, found in the soil as well as natural and engineered water systems.

Licensor is a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases.

Field of Use
The companies will co-develop a novel next-generation therapy for the eradication of H. pylori infection and RHB-204 for pulmonary nontuberculous mycobacteria (NTM) infections.

IPSCIO Record ID: 28650

License Grant
Under the License Agreement, the Licensor will have the responsibility for obtaining regulatory approval and the Licensee will have responsibility for the commercialization of products containing a combination of immediate release omeprazole and 325 mg or less of delayed release aspirin, including PA32540 and PA8140. Under the License Agreement, the Licensee has the exclusive right to commercialize Licensed products in the United States, with the Licensor retaining the right to commercialize Licensed products outside the United States. The Licensee will have responsibility for all sales, marketing and future development for the Licensed products. In addition, following approval of the NDA and completion of certain manufacturing milestones, the Licensee  will have responsibility for manufacturing the Licensed products for commercialization in the United States.
License Property
Products under the agreement include products containing a combination of immediate release omeprazole and 325 mg or less of delayed release aspirin, including PA32540 and PA8140, which are expected to be indicated for use for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers.

Stomach ulcers, also known as gastric ulcers, are open sores that develop on the lining of the stomach. Ulcers can also occur in part of the intestine just beyond the stomach. These are known as duodenal ulcers.

IPSCIO Record ID: 7295

License Grant
The Israeli Licensee/Buyer entered into an asset purchase Agreement with the Licensor/Seller, a publicly traded Australian company, pursuant to which the Licensor transferred all of its patents, tangible assets, production files, regulatory approvals and other data related to the Myoconda, Heliconda and Picoconda products to the Licensee.
License Property
The Licensee renamed these products RHB-104, RHB-105 and RHB-106, respectively.

RHB-104 for the treatment of Crohn's disease; RHB-105 for the treatment of Helicobacter pylori infection, a major cause of peptic ulcer disease; and RHB-106 for bowel preparation prior to abdominal procedures such as surgery or colonoscopy.

The Licensor further transferred to the Licensee products in process, product samples and raw materials.

The Agreement excluded from the transfer the rights to two other products of the Licensor that are not related to RHB-104, RHB-105 and RHB-106.

To the extent that the intellectual property associated with these two other products shall be required for the research, development, manufacture, registration, import/export, use, commercialization, distribution, sale and/or offer for sale of any of RHB-104, RHB-105 and RHB-106, the Licensor granted the Licensee an exclusive worldwide assignable right to such intellectual property for such purposes. The closing under this Agreement occurred on August 26, 2010.

Field of Use
The rights granted apply to the medical industry.

IPSCIO Record ID: 29176

License Grant
The University granted the an exclusive, worldwide and non-assignable except as specified license under the Invention to test, evaluate and develop the Licensed Product(s) in the Field of Use.
License Property
An employee of the Licensor has submitted a disclosure entitled “Treatment and Prevention of Helicobacter Pylori Infection with Hyperimmune Hen Egg Yolk Antibodies”.
Field of Use
Field of Use shall mean the use of Invention for Regulator approved human therapeutics in the treatment of Helicobacter Pylori.

IPSCIO Record ID: 463

License Grant
The information in this transaction was obtained from an executed Letter of Intent relative to a pending asset purchase agreement.

As part of the asset transfer, royalty bearing options are being made available to current Noteholder of the entity-to-be-acquired as well as the Series B Preferred Stockholders of the acquired company.  The royalties will be based upon sales of the drugs Helivax and Activax.

License Property
Helivax is a Helicobacter pylori vaccine.  H. Pylori is now recognized as the predominant cause of ulcers.

Activax is a combined multivalent vaccine for the prevention of Traveler's diarrheal diseases.

Field of Use
Travelers' diarrhea is a gastrointestinal illness that occurs in travelers. Travelers' diarrhea usually is caused by eating food contaminated with bacteria or, less commonly, with parasites or viruses.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.